spiolto respimat 2,5+2,5 mikrogram inhalationsvæske, opløsning
boehringer ingelheim int. gmbh - olodaterolhydrochlorid, tiotropiumbromidmonohydrat - inhalationsvæske, opløsning - 2,5+2,5 mikrogram
spiolto respimat 2,5+2,5 mikrogram inhalationsvæske, opløsning
paranova danmark a/s - olodaterolhydrochlorid, tiotropiumbromidmonohydrat - inhalationsvæske, opløsning - 2,5+2,5 mikrogram
spiolto respimat 2,5+2,5 mikrogram inhalationsvæske, opløsning
orifarm a/s - olodaterolhydrochlorid, tiotropiumbromidmonohydrat - inhalationsvæske, opløsning - 2,5+2,5 mikrogram
spiolto respimat 2,5+2,5 mikrogram inhalationsvæske, opløsning
2care4 aps - olodaterolhydrochlorid, tiotropiumbromidmonohydrat - inhalationsvæske, opløsning - 2,5+2,5 mikrogram
spiolto respimat 2,5+2,5 mikrogram inhalationsvæske, opløsning
medartuum ab - olodaterolhydrochlorid, tiotropiumbromidmonohydrat - inhalationsvæske, opløsning - 2,5+2,5 mikrogram
enurev breezhaler
novartis europharm ltd - glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - enurev breezhaler er indiceret som vedligeholdelsesbronkodilatorbehandling for at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).
seebri breezhaler
novartis europharm limited - glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - seebri breezhaler er indiceret som vedligeholdelsesbronkodilatorbehandling for at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).
tovanor breezhaler
novartis europharm limited - glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - tovanor breezhaler er indiceret som vedligeholdelsesbronkodilatorbehandling for at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
xoterna breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - adrenergica i kombinationer med antikolinergika inkl. tredobbelte kombination med kortikosteroider - xoterna breezhaler er indiceret som bronkodilaterende vedligeholdelsesbehandling at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (kol).